Tumor vaccine of recombinant murine EPS8 gene, and preparation method and application thereof

Abstract

The invention discloses a tumor vaccine of recombinant murine EPS8 gene, and further discloses a preparation method for the vaccine. The method comprises the following steps of: the clone of the recombinant murine rmHis-Eps8 gene and the construction of the prokaryotic expression vector for the recombinant murine rmHis-Eps8 gene: obtaining the gene fragment expressing the 440th-710th amino acid residues in the first extracellular region of the Eps8 gene by using RT-PCR, inserting pET28a prokaryotic expression vector, transferring into the Escherichia coli BL21 for a high-efficient expression, obtaining the vaccine through protein purification and condensation by ultrafiltration columns. The obtained vaccine can prolong the survival time of 4T1 tumor-bearing mouse, inhibiting the proliferation of 4T1 breast carcinoma cells in the mice, providing a new strategy for treatment of recurrent malignant tumors which are hard to treat clinically.

Description

technical field [0001] The invention relates to a vaccine, which can be applied to the prevention and diagnosis of diseases such as breast cancer, pancreatic cancer and colon cancer, and belongs to the technical field of vaccine genetic engineering. Background technique [0002] Over the past 20 years, studies on human tumor immune responses have shown that antigens expressed by tumor cells can cause specific cellular and humoral immune responses, but those who have the ability to spontaneously clear tumors through endogenous immune mechanisms are extremely rare. In 2004, Giorgio Parmiani pointed out that only 12% of patients had clinical response after treatment in the clinical phase I-II phase of the application of peptide-based vaccines in the treatment of patients with stage IV melanoma. In recent years, in cases in which autologous dendritic cells (DCs) were co-treated with peptides or tumor lysates compared with the above approaches, although the probability of patient...

AI Technical Summary

Problems solved by technology

[0002] For more than 20 years, research results on human tumor immune responses have shown that antigens expressed by tumor cells can cause specific cellular and humoral immune responses, but those who have the ability to spontaneously clear tumors through endogenous immune mechanisms are extremely rare

In fact, there are three mechanisms that lead to immune tolerance: cell line knockout, that is, specific lymphocytes are completely eliminated from the lymphocyte population; immune anergy, that is, specific lymphocytes exist, but their functions cannot be activated; immune Neglect, that is, immune function lymphocytes are present, but cannot be activated because they have not encountered self-antigens in the form of antigens

Images